Biomedico Financial Statements From 2010 to 2025
| ITGMF Stock | USD 0.48 0.00 0.00% |
Check Biomedico Hadarim financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomedico Hadarim's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biomedico financial statements analysis is a perfect complement when working with Biomedico Hadarim Valuation or Volatility modules.
Biomedico |
Biomedico Hadarim OTC Stock Price To Sales Analysis
Biomedico Hadarim's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Biomedico Hadarim Price To Sales | 14.15 X |
Most of Biomedico Hadarim's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomedico Hadarim is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Biomedico Hadarim has a Price To Sales of 14.1518 times. This is much higher than that of the sector and significantly higher than that of the Price To Sales industry. The price to sales for all United States stocks is notably lower than that of the firm.
Biomedico Hadarim Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biomedico Hadarim's current stock value. Our valuation model uses many indicators to compare Biomedico Hadarim value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biomedico Hadarim competition to find correlations between indicators driving Biomedico Hadarim's intrinsic value. More Info.Biomedico Hadarim is rated below average in current valuation category among its peers. It is rated fifth overall in price to book category among its peers . The ratio of Current Valuation to Price To Book for Biomedico Hadarim is about 15,697,770 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biomedico Hadarim's earnings, one of the primary drivers of an investment's value.About Biomedico Hadarim Financial Statements
Biomedico Hadarim stakeholders use historical fundamental indicators, such as Biomedico Hadarim's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biomedico Hadarim investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biomedico Hadarim's assets and liabilities are reflected in the revenues and expenses on Biomedico Hadarim's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biomedico Hadarim. Please read more on our technical analysis and fundamental analysis pages.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Biomedico OTC Stock
Biomedico Hadarim financial ratios help investors to determine whether Biomedico OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biomedico with respect to the benefits of owning Biomedico Hadarim security.